These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 28225313)
21. Pharmacokinetics, Clinical Efficacy, Safety Profile, and Patient-Reported Outcomes in Patients Receiving Subcutaneous Testosterone Pellets 900 mg for Treatment of Symptoms Associated With Androgen Deficiency. McMahon CG; Shusterman N; Cohen B J Sex Med; 2017 Jul; 14(7):883-890. PubMed ID: 28673432 [TBL] [Abstract][Full Text] [Related]
22. Injection of testosterone may be safer and more effective than transdermal administration for combating loss of muscle and bone in older men. Borst SE; Yarrow JF Am J Physiol Endocrinol Metab; 2015 Jun; 308(12):E1035-42. PubMed ID: 25898953 [TBL] [Abstract][Full Text] [Related]
23. Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial. Bhasin S; Travison TG; Pencina KM; O'Leary M; Cunningham GR; Lincoff AM; Nissen SE; Lucia MS; Preston MA; Khera M; Khan N; Snabes MC; Li X; Tangen CM; Buhr KA; Thompson IM JAMA Netw Open; 2023 Dec; 6(12):e2348692. PubMed ID: 38150256 [TBL] [Abstract][Full Text] [Related]
24. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment. Raynaud JP; Gardette J; Rollet J; Legros JJ BJU Int; 2013 May; 111(6):880-90. PubMed ID: 23294726 [TBL] [Abstract][Full Text] [Related]
25. Factors influencing prostate-specific antigen response among men treated with testosterone therapy for 6 months. Morgentaler A; Benesh JA; Denes BS; Kan-Dobrosky N; Harb D; Miller MG J Sex Med; 2014 Nov; 11(11):2818-25. PubMed ID: 25131184 [TBL] [Abstract][Full Text] [Related]
26. The long-term efficacy and safety of a testosterone mucoadhesive buccal tablet in testosterone-deficient men. Dinsmore WW; Wyllie MG BJU Int; 2012 Jul; 110(2):162-9. PubMed ID: 22288877 [TBL] [Abstract][Full Text] [Related]
28. New modalities of transdermal testosterone replacement. Basaria S; Dobs AS Treat Endocrinol; 2003; 2(1):1-9. PubMed ID: 15871550 [TBL] [Abstract][Full Text] [Related]
29. Testosterone supplementation does not worsen lower urinary tract symptoms. Pearl JA; Berhanu D; François N; Masson P; Zargaroff S; Cashy J; McVary KT J Urol; 2013 Nov; 190(5):1828-33. PubMed ID: 23764078 [TBL] [Abstract][Full Text] [Related]
30. Comparison of the steady-state pharmacokinetics, metabolism, and variability of a transdermal testosterone patch versus a transdermal testosterone gel in hypogonadal men. Mazer N; Bell D; Wu J; Fischer J; Cosgrove M; Eilers B; J Sex Med; 2005 Mar; 2(2):213-26. PubMed ID: 16422889 [TBL] [Abstract][Full Text] [Related]
31. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Wang C; Swerdloff RS; Iranmanesh A; Dobs A; Snyder PJ; Cunningham G; Matsumoto AM; Weber T; Berman N; J Clin Endocrinol Metab; 2000 Aug; 85(8):2839-53. PubMed ID: 10946892 [TBL] [Abstract][Full Text] [Related]
32. Serum testosterone levels in non-dosed females after secondary exposure to 1.62% testosterone gel: effects of clothing barrier on testosterone absorption. Stahlman J; Britto M; Fitzpatrick S; McWhirter C; Testino SA; Brennan JJ; Zumbrunnen TL Curr Med Res Opin; 2012 Feb; 28(2):291-301. PubMed ID: 22188558 [TBL] [Abstract][Full Text] [Related]
33. Retrospective investigation of testosterone undecanoate depot for the long-term treatment of male hypogonadism in clinical practice. Conaglen HM; Paul RG; Yarndley T; Kamp J; Elston MS; Conaglen JV J Sex Med; 2014 Feb; 11(2):574-82. PubMed ID: 24279472 [TBL] [Abstract][Full Text] [Related]
34. Effect of application site, clothing barrier, and application site washing on testosterone transfer with a 1.62% testosterone gel. Stahlman J; Britto M; Fitzpatrick S; McWhirter C; Testino SA; Brennan JJ; Zumbrunnen TL Curr Med Res Opin; 2012 Feb; 28(2):281-90. PubMed ID: 22188557 [TBL] [Abstract][Full Text] [Related]
35. Skin reactions in a phase 3 study of a testosterone topical solution applied to the axilla in hypogonadal men. Muram D; Melby T; Alles Kingshill E Curr Med Res Opin; 2012 May; 28(5):761-6. PubMed ID: 22458919 [TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal men. Kaufman JM; Miller MG; Garwin JL; Fitzpatrick S; McWhirter C; Brennan JJ J Sex Med; 2011 Jul; 8(7):2079-89. PubMed ID: 21492400 [TBL] [Abstract][Full Text] [Related]
37. Compounded percutaneous testosterone gel: use and effects in hypogonadal men. Cutter CB J Am Board Fam Pract; 2001; 14(1):22-32. PubMed ID: 11206690 [TBL] [Abstract][Full Text] [Related]
38. Adverse events during testosterone replacement therapy in 95 young hypogonadal thalassemic men. De Sanctis V; Soliman AT; Daar S; Di Maio S Acta Biomed; 2019 May; 90(2):228-232. PubMed ID: 31125000 [TBL] [Abstract][Full Text] [Related]
39. Testosterone replacement therapy can increase circulating endothelial progenitor cell number in men with late onset hypogonadism. Liao CH; Wu YN; Lin FY; Tsai WK; Liu SP; Chiang HS Andrology; 2013 Jul; 1(4):563-9. PubMed ID: 23653307 [TBL] [Abstract][Full Text] [Related]
40. Impact of Testosterone Solution 2% on Ejaculatory Dysfunction in Hypogonadal Men. Maggi M; Heiselman D; Knorr J; Iyengar S; Paduch DA; Donatucci CF J Sex Med; 2016 Aug; 13(8):1220-6. PubMed ID: 27436077 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]